SCHEMBL30009302

SCHEMBL30009302

O=C(c1ccncc1)N1CC=C(c2ccnc3[nH]ccc23)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 13/20 0.52
CDK9 P50750 4/20 0.51
CCNT1 O60563 3/20 0.51
NAMPT P43490 1/20 0.46
CHEK1 O14757 2/20 0.44
MAP4K4 O95819 2/20 0.44
PIM1 P11309 2/20 0.44
PRKACA P17612 2/20 0.44
CLK2 P49760 2/20 0.44
GSK3B P49841 2/20 0.44
CDK5 Q00535 2/20 0.44
PRKAA1 Q13131 2/20 0.44
ROCK1 Q13464 2/20 0.44
DYRK1A Q13627 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
DAPK3 O43293 1/20 0.44
KDR P35968 1/20 0.44
MAP2K2 P36507 1/20 0.44
MAPK8 P45983 1/20 0.44
CSNK1A1 P48729 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14493878 0.85 CCNT1 (0.50) JAK1CDK9CCNT1CHEK1MAP4K4
SCHEMBL30009520 0.82 JAK1 (0.62) JAK1CHEK1MAP4K4PIM1PRKACA
SCHEMBL14493885 0.80 JAK1 (0.57) JAK1CDK9CCNT1JAK3
SCHEMBL10125393 0.80 JAK1 (0.64) JAK1CDK9CCNT1CHEK1MAP4K4
SCHEMBL30009343 0.80 JAK1 (0.48) JAK1CDK9CCNT1CHEK1MAP4K4
SCHEMBL3602461 0.80 JAK1 (0.65) JAK1CDK9CCNT1
SCHEMBL14420789 0.79 JAK1 (0.50) JAK1CDK9CCNT1
SCHEMBL23485739 0.78 JAK1 (0.84) JAK1
SCHEMBL29430994 0.77 JAK1 (0.47) JAK1CDK9CCNT1CHEK1MAP4K4
SCHEMBL27819451 0.75 HTR1A (0.46) JAK1CDK9CCNT1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK1 83/4885CDK9 330/4885CCNT1 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.